Dr Ian Flinn at ASH 2014: Phase I study of duvelisib in patients with relapsed/refractory indolent non-Hodgkin lymphoma

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses a phase I study of the novel PI3k-δ,γ inhibitor, duvelisib (IPI-1... Author: EMJ Added: 01/26/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts